2,049 results on '"DREGER, PETER"'
Search Results
2. Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC)
3. How risky is a second allogeneic stem cell transplantation?
4. Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
5. Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
6. Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT
7. Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison
8. Chronic Lymphocytic Leukemia
9. Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years
10. Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients
11. PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation
12. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma
13. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation
14. Correction: Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT
15. High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders
16. Relevance of donor-specific HLA antibodies in hematopoietic cell transplantation
17. Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation
18. Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial
19. Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
20. Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis
21. Prehabilitative high-intensity interval training and resistance exercise in patients prior allogeneic stem cell transplantation
22. First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma
23. Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
24. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
25. The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature
26. Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study
27. Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis Aged 70 Years or Older: A Study from the German Registry for Stem Cell Transplantation
28. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
29. Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience
30. Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters
31. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial
32. Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis
33. Comparing the value of mono- vs coculture for high-throughput compound screening in hematological malignancies
34. EASIX-1year and late mortality after allogeneic stem cell transplantation
35. Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut
36. Thiotepa–fludarabine–treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial
37. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents.
38. Chronic Lymphocytic Leukaemia
39. Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study
40. Cure of intravascular NK/T-cell lymphoma of the central nervous system by allogeneic hematopoietic cell transplantation
41. Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia
42. Treatment of chronic COVID‐19 with convalescent/postvaccination plasma in patients with hematologic malignancies
43. Supplementary Tables 1 from Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study
44. Data from Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study
45. Supplementary Figure 1 from Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study
46. Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight
47. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma
48. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial
49. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.
50. Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.